专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10301292B2 Bicyclic compound 有权
公开(公告)号：US10301292B2
公开(公告)日：2019-05-28
申请号：US15529816
申请日：2015-11-25
申请人： Takeda Pharmaceutical Company Limited
发明人： Ryo Mizojiri , Hiroshi Banno , Moriteru Asano , Daisuke Tomita , Noriyuki Nii , Hironobu Maezaki , Michiko Tawada
IPC分类号： C07D413/04 , C07D413/14 , A61K31/343 , A61K31/381 , A61K31/416 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/443 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/517 , A61K31/5377 , C07D231/56 , C07D333/56 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D263/54 , C07D498/04 , C07D307/81 , C07D263/57 , C12N15/09
摘要： Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

2. 发明申请

US20150045351A1 TRICYCLIC COMPOUND 有权
标题翻译：三聚体化合物
公开(公告)号：US20150045351A1
公开(公告)日：2015-02-12
申请号：US14381347
申请日：2013-03-06
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： Tomokazu Kusumoto , Shigekazu Sasaki , Hironobu Maezaki
IPC分类号： C07D495/06 , C07D491/06 , C07D487/06
CPC分类号： C07D495/06 , C07D487/06 , C07D491/06
摘要： The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action.The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.
摘要翻译：本发明提供具有优良的5-羟色胺5-HT 2C受体激活作用的化合物。本发明涉及由式（1）表示的化合物，其中环A是任选具有取代基的芳族碳环或任选具有取代基的芳族杂环，X是-N（R 1） - ，-O- 当环A是任选具有取代基的芳族碳环，则R1是氢原子，任选具有取代基的烷基等，当环A是任选具有取代基的芳族杂环时，那么R 1是氢原子，任选具有取代基的烷基，任选具有取代基的环烷基等是单键或双键，n是整数 0,1或2，或其盐。

3. 发明授权

US12084436B2 Heterocyclic compound 有权
公开(公告)号：US12084436B2
公开(公告)日：2024-09-10
申请号：US17426971
申请日：2020-01-29
申请人： Takeda Pharmaceutical Company Limited
发明人： Masahiro Ito , Takeshi Yamamoto , Keiko Kakegawa , Hideyuki Sugiyama , Tohru Miyazaki , Yasuyoshi Arikawa , Tomohiro Okawa , Jinichi Yonemori , Osamu Kubo , Akinori Toita , Takuto Kojima , Fumiaki Kikuchi , Minoru Sasaki , Misaki Homma , Yasuhiro Imaeda , Hironobu Maezaki , Shiinobu Sasaki , Ayumu Sato , Hirotaka Kamitani , Yasutomi Asano , Hironori Kokubo , Masato Yoshikawa
IPC分类号： C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
CPC分类号： C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):

wherein each symbol is as described in the description, or a salt thereof.

4. 发明授权

US11236099B2 Heterocyclic compound 有权
公开(公告)号：US11236099B2
公开(公告)日：2022-02-01
申请号：US16622632
申请日：2018-06-19
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： Kazuaki Takami , Masaki Seto , Shinobu Sasaki , Haruhi Ando , Masaki Ogino , Tomoko Ohashi , Toshihiro Imaeda , Ikuo Fujimori , Yasuhiro Tsukimi , Masami Yamada , Kenichiro Shimokawa , Takeshi Wakabayashi , Masataka Murakami , Makoto Fushimi , Tomohiro Okawa , Jinichi Yonemori , Tomohiro Ohashi , Hideo Suzuki , Hironobu Maezaki , Ayumu Sato , Yasutomi Asano , Steve Swann
IPC分类号： C07D491/048 , A61K31/4355 , A61P1/10
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

5. 再颁专利

USRE49686E1 Nitrogen-containing heterocyclic compound and use of same 有权
公开(公告)号：USRE49686E1
公开(公告)日：2023-10-10
申请号：US17076227
申请日：2020-10-21
申请人： Takeda Pharmaceutical Company Limited
发明人： Junya Shirai , Hideyuki Sugiyama , Taku Kamei , Hironobu Maezaki
IPC分类号： C07D401/04 , C07D207/14 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/14 , C07D417/08
CPC分类号： C07D401/04 , C07D207/14 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/14 , C07D417/08
摘要： The present invention relates to a compound represented by the formula

wherein ring A is a nitrogen-containing heterocycle;

ring B is an aromatic ring optionally having substituent(s);

ring D is an aromatic ring optionally having substituent(s);

L is a group represented by the formula

R2, R3, R4a ′ and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain;
R1 is a hydrogen atom or a substituent;
m and n are each independently an integer of 0 to 5;
m+n is an integer of 2 to 5; and
is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

6. 发明申请

US20220017530A1 HETEROCYCLIC COMPOUND 有权
公开(公告)号：US20220017530A1
公开(公告)日：2022-01-20
申请号：US17475733
申请日：2021-09-15
申请人： Takeda Pharmaceutical Company Limited
发明人： Kazuaki Takami , Masaki Seto , Shinobu Sasaki , Haruhi Ando , Masaki Ogino , Tomoko Ohashi , Toshihiro Imaeda , Ikuo Fujimori , Yasuhiro Tsukimi , Masami Yamada , Kenichiro Shimokawa , Takeshi Wakabayashi , Masataka Murakami , Makoto Fushimi , Tomohiro Okawa , Jinichi Yonemori , Tomohiro Ohashi , Hideo Suzuki , Hironobu Maezaki , Ayumu Sato , Yasutomi Asano , Steve Swann
IPC分类号： C07D491/048 , A61P1/10 , A61K31/4355
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

7. 发明授权

US10252997B2 Monocyclic compound 有权
公开(公告)号：US10252997B2
公开(公告)日：2019-04-09
申请号：US15563128
申请日：2016-03-30
申请人： Takeda Pharmaceutical Company Limited
发明人： Ryo Mizojiri , Moriteru Asano , Daisuke Tomita , Hiroshi Banno , Michiko Tawada , Noriyuki Nii , Krista E. Gipson , Hironobu Maezaki , Shuntarou Tsuchiya , Mayumi Imai , Yuichiro Amano
IPC分类号： C07D213/65 , A61K31/165 , A61K31/167 , A61K31/277 , A61K31/381 , A61K31/402 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/427 , A61K31/44 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/451 , A61K31/454 , A61K31/4965 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , C07D213/75 , C07D213/81 , C07D231/12 , C07D333/20 , C07D401/04 , C07D237/14 , C07D239/34 , C07D409/04 , C07D413/04 , C07D241/18 , C07D417/04 , C07C233/18 , C07C233/47 , C07D261/08 , C07D263/32 , C07D263/42 , C07D207/08 , C07D207/12 , C07D277/34 , C07D211/44 , C07D213/643 , C07D213/69 , C07C233/25 , C07C255/54 , C07D211/46 , C07D213/74 , C07D401/12 , C12N9/99 , C12N15/09
摘要： The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

8. 发明授权

US12012419B2 Heterocyclic compound 有权
公开(公告)号：US12012419B2
公开(公告)日：2024-06-18
申请号：US17280634
申请日：2019-09-27
申请人： Takeda Pharmaceutical Company Limited
发明人： Shinobu Sasaki , Yasutomi Asano , Hironobu Maezaki , Ayumu Sato
IPC分类号： C07D498/04 , A61P1/00
CPC分类号： C07D498/04 , A61P1/00
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I):

wherein each symbol is as described in the specification, or a salt thereof.

9. 发明授权

US11584737B2 Heterocyclic compound 有权
公开(公告)号：US11584737B2
公开(公告)日：2023-02-21
申请号：US17042394
申请日：2019-03-28
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： Koji Ono , Masahiro Ito , Toshio Tanaka , Moriteru Asano , Takaharu Hirayama , Jun Fujimoto , Nobuki Sakauchi , Yasuhiro Hirata , Akinori Toita , Nao Morishita , Hironori Kokubo , Yasuhiro Imaeda , Hironobu Maezaki , Douglas Robert Cary , Ryo Mizojiri , Nobuo Cho , Hiroshi Banno , Hidekazu Tokuhara , Yasuyoshi Arikawa
IPC分类号： C07D401/14 , C07D403/14 , A61P35/00 , C07D213/84 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/10 , C07D487/10 , C07D495/10
摘要： Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

10. 再颁专利

USRE48334E1 Nitrogen-containing heterocyclic compound and use of same 有权
公开(公告)号：USRE48334E1
公开(公告)日：2020-12-01
申请号：US15445251
申请日：2017-02-28
申请人： Takeda Pharmaceutical Company Limited
发明人： Junya Shirai , Hideyuki Sugiyama , Taku Kamei , Hironobu Maezaki
IPC分类号： C07D401/04 , C07D207/14 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/14 , C07D417/08
CPC分类号： C07D401/04 , C07D207/14 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/14 , C07D417/08
摘要： The present invention relates to a compound represented by the formula

wherein ring A is a nitrogen-containing heterocycle;
ring B is an aromatic ring optionally having substituent(s);
ring D is an aromatic ring optionally having substituent(s);
L is a group represented by the formula

R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain;
R1 is a hydrogen atom or a substituent;
m and n are each independently an integer of 0 to 5;
m+n is an integer of 2 to 5; and
is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式